Unicycive Therapeutics (Nasdaq: UNCY) announced resubmission of its 505(b)(2) New Drug Application (NDA) to the FDA for oxylanthanum carbonate (OLC), a phosphate binder for treating hyperphosphatemia in patients with chronic kidney disease on dialysis. A new PDUFA target date is expected in 1H 2026, within 30 days of the resubmission. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at b2idigital.com/unicycive. The resubmission reflects progress by the o

4.2K views · 797 reactions | Although the digital age has brought us benefits, there are drawbacks, especially for younger generations. Learning to manage and balance our online presence is essential, and a good way to start is to pause before we begin any activity. This helps us to observe and consider our actions, and to make the best decisions. @heartfulness #Daaji #Pause #Observe #Action #Decision | Kamlesh D Patel | Facebook

B2i Digital is proud to be named the Official Marketing Partner for Virtual Investor Conferences (VIC), the long-running online investor event series owned and operated by OTC Markets Group Inc. Our partnership begins this week with two upcoming events: Small Cap Growth Virtual Investor Conference – December 9, 2025 Life Sciences Virtual Investor Forum – December 11, 2025 Presenting Companies – December 9 Small Cap Growth Conference Northstar Clean Technologies Inc. Frontera Energy Dotz Nano Ltd

124 reactions | Unicycive Therapeutics (Nasdaq: UNCY) announced that...

4K views · 109 reactions | Head over to Reliance Digital at Phoenix...